These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15548969)
1. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Ruiz JC; Campistol JM; Grinyó JM; Mota A; Prats D; Gutiérrez JA; Henriques AC; Pinto JR; García J; Morales JM; Gómez JM; Arias M Transplantation; 2004 Nov; 78(9):1312-8. PubMed ID: 15548969 [TBL] [Abstract][Full Text] [Related]
2. Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Ruiz JC; Campistol JM; Mota A; Prats D; Gutiérrez JA; Castro A; García J; Morales JM; Grynió JM; Gómez JM; Arias M Transplant Proc; 2003 Aug; 35(5):1669-70. PubMed ID: 12962750 [TBL] [Abstract][Full Text] [Related]
3. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Stallone G; Di Paolo S; Schena A; Infante B; Grandaliano G; Battaglia M; Gesualdo L; Schena FP Transplantation; 2003 Apr; 75(7):998-1003. PubMed ID: 12698087 [TBL] [Abstract][Full Text] [Related]
4. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP; Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789 [TBL] [Abstract][Full Text] [Related]
5. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM; Kobashigawa J; Klintmalm G Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899 [TBL] [Abstract][Full Text] [Related]
6. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
7. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
8. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Goldfarb DA J Urol; 2005 Jun; 173(6):2106-7. PubMed ID: 15879857 [No Abstract] [Full Text] [Related]
9. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Bakker RC; Hollander AA; Mallat MJ; Bruijn JA; Paul LC; de Fijter JW Kidney Int; 2003 Sep; 64(3):1027-34. PubMed ID: 12911553 [TBL] [Abstract][Full Text] [Related]
10. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF; Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978 [TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Flechner SM; Gurkan A; Hartmann A; Legendre CM; Russ GR; Campistol JM; Schena FP; Hahn CM; Li H; Korth-Bradley JM; Tai SS; Schulman SL Transplantation; 2013 May; 95(10):1233-41. PubMed ID: 23689085 [TBL] [Abstract][Full Text] [Related]
12. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
13. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF; Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398 [TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive treatment and progression of histologic lesions in kidney allografts. Morales JM Kidney Int Suppl; 2005 Dec; (99):S124-30. PubMed ID: 16336565 [TBL] [Abstract][Full Text] [Related]
15. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437 [TBL] [Abstract][Full Text] [Related]
18. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Solez K; Vincenti F; Filo RS Transplantation; 1998 Dec; 66(12):1736-40. PubMed ID: 9884269 [TBL] [Abstract][Full Text] [Related]
19. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study. Han F; Wu J; Huang H; Zhang X; He Q; Wang Y; Wang S; Wang H; Chen J Exp Clin Transplant; 2011 Feb; 9(1):42-9. PubMed ID: 21605022 [TBL] [Abstract][Full Text] [Related]
20. Molecular and structural consequences of early renal allograft injury. Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]